Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Artavazd Arumov Ph.D

Principal

Ryan Baker

Chief Financial Officer

Sam Chen

Associate

Nan Chen

Principal

Phil DiGiacomo

VP

Anna French

Partner

Jinda Gao

Executive Director

William Hu

Managing Partner

Duane Kuang

Co-Founder & Managing Partner

Grace Lee

Partner

Nisa Leung

Managing Partner

Shuo Mao

vice_president

Mark McDade

Partner

Will Mcconnell

VP

Gary Rieschel

Co-Founder & Managing Partner

Amy Tang

Venture Partner

Shiyu Wang

Partner

Bonnie Wang

Principal

Jing Wu

Partner

Kuantai Yeh

Partner

Janet Yu Ph.D

Partner

Oscar Zhang

Principal

Alex Zhou

Partner

Past deals in Growth Stage

Hochuen Medical was founded in 2015 by Dr. Robin Liu, an entrepreneur in IVD medical and microfluidics fields, and Eric Zeng, an expert in the electronics OEM industry. The founding management team has an average of more than 20 years of management experience in manufacturing of microfluidic devices, medical disposables, and consumer electronic products. Dr. Robin Liu, co-founder and president of Hochuen Medical, has more than 20 years of experience in the IVD and microfluidic industry, with experience at Motorola, CombiMatrix, GenMark, Beckman Coulter/Danaher, etc. Dr. Liu brings both experience in R&D and production management in the fields of molecular diagnosis, immunoassays, hematology, urinalysis, etc

Yike Polymers

Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.

Gaugene

Series B in 2022
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.

LaNova Medicines

Series B in 2022
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Boulder Care

Series B in 2022
Boulder Care, Inc. is a telemedicine-based platform focused on treating opioid addiction through a combination of medication and peer support. Founded in 2017 and located in Portland, Oregon, the company provides comprehensive services that include patient support, medication management, and psychosocial services. By leveraging digital health technology, Boulder Care aims to improve access to effective treatment for individuals struggling with opioid use, enhancing the experience for both patients and their care teams. The organization serves a diverse clientele, including patients, providers, and various health organizations, contributing to the advancement of the behavioral health industry.

Point One

Series B in 2022
Building the next-gen consumer products!

BUD

Series B in 2022
Founded in 2019 by former Snap engineers, Risa Feng and Shawn Lin, Singapore-headquartered BUD is a leading global metaverse UGC platform encouraging users to create and share 3D interactive experiences with its easy-to-use creation tools. Since its global launch in November 2021, BUD skyrocketed to the list of top 10 social apps in more than 38 countries around the world including North America, Southeast Asia and South America. Millions of 3D content has been created and traded on the platform. BUD has become a digital social hub where millions of people come to create, play and hangout.

Yike Polymers

Series B in 2022
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.

MeetFuture China

Series B in 2022
MeetFuture China is a technology-driven company that supplies automated transmission systems for the pan-semiconductor industry. It provides automation solutions for leading companies in the semiconductor field since 2016 and provided a highly advantageous overall for industrial upgrading and development with independent and controllable core technologies.

Medilink Therapeutics

Series B in 2022
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Deep View Technology

Series B in 2022
Beijing Deep View Technology Co., Ltd. engaged in research on 3D computer vision algorithm. The company is based in Beijing, China.

EigenCOMM

Series C in 2022
Eigencomm is dedicated to the development and sales of cellular IoT chips.

Zhenge Biotech

Series C in 2022
Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

Korro Bio

Series B in 2022
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

CureGenetics

Series B in 2022
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

TUNGEE

Series B in 2021
Guangzhou Tungee Technology Co.,Ltd., a software as a service (SaaS) company, develops intelligent sales cloud platform. It provides leads mining, business opportunity engagement, customer relationship management, and order analysis for enterprises. The company offers Tungee intelligent sales cloud platform , outbound leads, inbound leads, engage, cloud-based call center, intelligent call, and CRM products. It also offers Tungee galaxy, prophecy, and discernment solutions. Guangzhou Tungee Technology Co.,Ltd. was founded in 2016 and is based in Panyu, China.

InfStones

Series B in 2021
Infinity Stones is a Silicon Valley-based company that provides cloud management services and security solutions for blockchains. They are blockchain infrastructure architects with proven track records in the industry. Their team is composed of tech leads, management experts, and financial professionals from tech giants like Google, Oracle, and Intel. Infinity Stones is currently hosting nodes for high net worth individuals, institutional investors, foundations, and universities and research institutions. They make sure every investment with us is secure, and investors can expect returns with consistency. It was founded in 2018 and is headquartered in Palo Alto, California.

Wholee

Series B in 2021
Wholee is a member-only zero-markup store.

DPTechnology

Series B in 2021
DPTechnology, founded in 2018 and based in Beijing, China, specializes in micro-scale industrial design through advanced molecular simulation technology. The company has developed a platform that integrates artificial intelligence with molecular simulation algorithms, aiming to enhance industrial and medical research. By providing users with innovative scientific tools, DPTechnology promotes efficiency and creativity in exploring complex research challenges, thereby establishing a new paradigm in both industrial research and clinical applications.

Cornerstone Robotics

Series B in 2021
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

Platelet BioGenesis

Series B in 2021
Platelet BioGenesis is a biotechnology company focused on producing donor-independent human platelets from pluripotent stem cells for clinical use. Founded in 2014 and based in Cambridge, Massachusetts, the company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. Platelet BioGenesis distributes these bioreactor-produced platelets to hospitals and blood banks, aiming to provide a reliable source of platelets for patients worldwide. By specializing in the fields of platelets and drug discovery, the company is addressing critical needs in the medical community related to blood supply and treatment options.

Genlight

Series B in 2021
Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.

Okeanos Technology

Series B in 2021
Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company's primary offerings include modified nucleotides, unnatural amino acids, heterocycles, and fluorescent and labeling reagents. Okeanos supplies these products to leading pharmaceutical companies, earning a strong reputation for quality and reliability. The firm focuses on providing clients with a diverse range of chemical compounds and biochemical reagents, particularly in the realms of sequencing and synthetic biology.

Qingflow

Series B in 2021
Qingflow is a software-as-a-service platform that enables users to create management systems. Qingflow is located in Minhang District, Shanghai.

Sunyur

Series B in 2021
Sunyur is an e-purchase solution provider.

Ventyx Biosciences

Series B in 2021
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Alamar Biosciences

Series B in 2021
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

moodytiger

Series B in 2021
Moody Tiger is an international activewear brand for children. Moody Tiger was founded in 2018.

Gyenno Science

Series B in 2021
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.

Lingyi Zhihui

Series B in 2021
Zuoshouyisheng's AI ​​doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. Zuoshouyisheng mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.

Abogen Biosciences

Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Berry Oncology

Series B in 2021
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Kingsware

Series B in 2021
Kingsware specializes in developing a robotic process automation system. It is committed to building an enterprise-level safe robot management platform. Its product follows the design concept of safe, easy-to-use, powerful, stable, and efficient, and the system can be deployed and controlled in a large-scale, highly integrated enterprise complex environment.

Insilico Medicine

Series C in 2021
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.

Health Biotech

Series B in 2021
Beijing Health Biotech Co. Ltd. develops diagnostic and therapeutic products for diagnosis, treatment, and monitoring of Alzheimer's disease. The company offers diagnostic and therapeutic products, such as vitamins detection, Alzheimer's disease detection and treatment, prostate AA detection, ceramides test, therapeutic drug monitoring, and screening of neonatal genetic metabolic diseases for Alzheimer's disease, cardiovascular disease, urinary disease, genetic metabolic disease, therapeutic drug monitoring, metabolite detection, steroid hormone detection, trace element quantitative detection, vitamin family detection, and microbiological identification. It also offers clinical testing and research services. The company was founded in 2016 and is based in Beijing, China.

Hope Medicine

Series B in 2021
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Just Medical

Series B in 2021
Just Medical is an artificial orthopedic implant device and system developer.

Yidao Biotechnology

Series C in 2021
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

TUNGEE

Series C in 2021
Guangzhou Tungee Technology Co.,Ltd., a software as a service (SaaS) company, develops intelligent sales cloud platform. It provides leads mining, business opportunity engagement, customer relationship management, and order analysis for enterprises. The company offers Tungee intelligent sales cloud platform , outbound leads, inbound leads, engage, cloud-based call center, intelligent call, and CRM products. It also offers Tungee galaxy, prophecy, and discernment solutions. Guangzhou Tungee Technology Co.,Ltd. was founded in 2016 and is based in Panyu, China.

PR Measurement

Series C in 2021
P&R Measurement Technology Co., Ltd., established in 2011 and based in Zhuhai, China, specializes in the research, development, and application of advanced measurement and control technology. The company provides testing and automation solutions across various sectors, including motors, household appliances, consumer electronics, and energy power. With over 300 independent intellectual property rights, P&R Measurement has earned recognition as a national high-tech enterprise and has received multiple certifications, including ISO9001:2015. The firm focuses on engineering signal processing, acoustic and vibration testing, and structural analysis, offering custom and semi-custom testing equipment and consulting services. P&R Measurement also collaborates with universities and research institutions to enhance its technological capabilities. It operates subsidiaries in multiple locations, including Guangzhou, Suzhou, Hong Kong, and the United States, and has developed comprehensive solutions that are widely acknowledged by industry clients, contributing to its reputation in the testing and automation landscape.

Tasogare

Series B in 2021
Tasogare Coffee is a Japan-based company specializing in the distribution of high-quality coffee. The company's focus is on providing premium coffee products to customers, ensuring a commitment to quality in its offerings. Through careful sourcing and distribution practices, Tasogare aims to deliver a superior coffee experience.

SinoUnited Health

Series C in 2021
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.

Castbox

Series C in 2021
Castbox is an award-winning global podcast platform that enables anyone to easily find, access, create and enjoy spoken audio content. Castbox gives users access to endless content in multiple languages, anywhere, through any device. Castbox’s proprietary technology includes features like curated podcast recommendations and in-audio deep search to customize the listening experience.

Matrixport

Series C in 2021
Matrixport is your gateway to digital economy where you can trade, custody, invest and borrow crypto assets all in one stop. With rich industry resources and leading technology capabilities, Matrixport aims to create the next generation digital financial service platform. Their vision is to enable a more open and equal financial system using blockchain technologies. Matrixport has launched trading, digital asset custody, and cryptocurrency lending service for clients around the world, with even more innovative product offerings to come. Matrixport is headquartered in Singapore with offices worldwide.

Booming Tech

Series C in 2021
Booming Tech is a cloud-based platform that specializes in game development and virtual reality. It provides tools for creators to design and innovate within virtual environments, catering to various applications, including gaming, industrial simulations, and other immersive experiences. The platform features a robust server architecture that ensures players can engage in real-time, stable interactions regardless of their geographical locations. By focusing on both entertainment and practical applications, Booming Tech supports a diverse range of virtual world creation, enabling users to explore new possibilities in digital interaction.

Zion Pharma

Series B in 2021
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Alpha Biopharma

Series B in 2021
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on the research and development of innovative therapeutics. The company is actively developing AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with non-small cell lung cancer who have epidermal growth factor receptor (EGFR) mutations and central nervous system metastases. Alpha Biopharma collaborates with prominent domestic and international pharmaceutical companies to enhance the reliability of its product development. The company employs a strong scientific consulting and management team to optimize its drug development strategies, emphasizing a comprehensive approach that includes research, market positioning, and intellectual property protection. Additionally, Alpha Biopharma partners with top contract research organizations, contract manufacturing organizations, hospitals, and institutes to ensure efficient and organized program implementation, supported by a robust project management system.

Icosavax

Series B in 2021
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

imToken

Series B in 2021
imToken Pte. Ltd. is a Singapore-based company that specializes in developing a blockchain-based cryptocurrency wallet and digital asset management tools. Founded in 2016, imToken enables users to manage multi-chain assets and facilitates secure token exchanges within its wallet. The platform features a DApp browser that supports decentralized token-to-token transactions, enhancing the user experience in the blockchain ecosystem. Over the years, imToken has garnered a global user base, becoming one of the largest Ethereum wallets in the world. The company operates as a subsidiary of Hangzhou Rongshi Technology Co., Ltd. and is dedicated to making blockchain technology accessible and user-friendly for a broader audience.

Zhenge Biotech

Series B in 2021
Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

Cool Academy

Series B in 2021
Cool College is a Beijing-based software-as-a-service(SaaS) developer for employee training services.

Yuanbao Tech

Series C in 2021
Beijing Yuanbao Technology Co., Ltd., a technology company, provides cyber security assessment consulting, network security detection, and cyber security insurance solutions. It offers network security risk monitoring and evaluation, and network security defense system construction advisory services; risk assessment and risk mitigation solutions; model development and technical services for cyber security insurance products for insurance and reinsurance companies; assists insurance companies to conduct cyber security risk assessment for insured customers. The company was founded in 2018 and is based in Beijing, China.

Newsoara

Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Hangzhou Weier

Series B in 2021
Weier Technology Co., Ltd, also known as Weier Science, designs and develops robots and software. Its human- machine interaction technology caters e-commerce platforms with customer service, sales and marketing, shopping guide, and customer relations management. Weier Technology Co., Ltd was founded in 2016 and is based in Hangzhou, China. Weier Technology operates in the augmented reality and virtual reality industry. The company is based in Shanghai, China.

Singular Medical

Series B in 2021
Singular Medical is a technology company specializing in R&D and industrialization of cardiac rhythm management (CRM) products. The company builds a complete technical platform and is a supplier of full line of CRM products, which provides a complete range of solutions, from detection to follow-up for large amounts of cardiac patients.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. develops anti-cancer academic platform for cancer patients. The company is based in Shanghai, China.

Plum

Series B in 2021
Plum is an e-commerce platform for second-hand fashion products. It works as a one-stop consignment service platform that provides filming, sales, customer service, sale, and a full set of consignment services. Plum was founded on 2015 and is headquartered in Beijing, China.

Morewis

Series B in 2021
Morewis is a Enterprise service provider.

Bouffalo Lab

Series B in 2021
Bouffalo Lab designs and develops semiconductor chips. The company offers integrated Wi-Fi chipsets for low-power and high-performance application development and other products. Its products are used in smart homes, cities, manufacturing, robots, and wearable systems, as well as communication equipment and in-vehicle intelligent systems. The company is based in Shanghai, China.

Yunji Technology

Series C in 2021
Yunji Technology is a Chinese robot company that builds a commercial service robot capable of delivering goods.

WeRide

Series B in 2021
Guangzhou WeRide Technology Co., Ltd. develops autonomous driving technology for level 4 AD cars. The company also develops own AD hardware solution to fit on cars for surround sensor coverage and full spectrum. The company was founded in 2017 and is headquartered in Guangzhou, China.

Vistel

Series B in 2021
Vistel is a technology-based firm that focuses on the use of artificial intelligence (AI) in the medical field. Vistel was founded in 2016 by Sun Yuhui and Ding Dayong.

Kira Pharma

Series B in 2021
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Insight Lifetech

Series C in 2020
Insight Lifetech Co., Ltd. (Shenzhen) is headquartered in China.

dMed

Series C in 2020
dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Nice Tuan

Series C in 2020
Nice Tuan is an e-commerce platform that specializes in providing daily groceries and a variety of household products. The company collaborates with local residential communities to source items from nearby warehouses and producers, ensuring a wide selection of fresh produce and essential goods for residents. By focusing on creating a convenient and efficient community e-commerce ecosystem, Nice Tuan aims to enhance the shopping experience for local consumers while supporting local suppliers.

Elevation Oncology

Series B in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.

ZEGOCLOUD

Venture Round in 2020
Shenzhen Zego Technology Co., Ltd. is a company based in Shenzhen, China, that specializes in real-time cloud streaming services for audio and video communications. Founded in 2015, Zego offers a comprehensive platform that supports various functionalities, including one-to-one video calls, live broadcasting, and multi-party video conferencing. The platform also provides services for real-time audio streaming, voice chatrooms, and recording and archiving of events such as bank account openings and interviews. Zego targets enterprise and mobile application developers, focusing on delivering stable and high-quality voice and video services across diverse sectors, including social media, online education, and telemedicine. Additionally, the company provides a software development kit (SDK) to facilitate the integration of its services into other applications.

BRONCUS

Series C in 2020
Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

Talaris Therapeutics

Series B in 2020
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Petkit

Series C in 2020
Shanghai PETKIT Network Technology Co., Ltd. Develops and manufactures pet care products. It offers smart antibacterial bowls, smart feeders, smart drinking fountains, pet accompanying cups, smart leashes, smart cat brand dog tags, smart pet companions, multifunctional cat claw plates, etc.; cat and dog tags that record, analyze, and track the pet's usual sports behavior data; and toys. Shanghai PETKIT Network Technology Co., Ltd. was founded in 2013 and is based in Shanghai, China.

Shukun Technology

Series B in 2020
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

Antengene Corporation

Series C in 2020
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in developing innovative oncology therapies aimed at treating various types of cancer. Its product pipeline includes ATG-008, an orally available mTOR kinase inhibitor for advanced solid tumors and hematological malignancies, and ATG-010, a compound targeting the XPO1 protein for hematologic cancers like multiple myeloma. Additionally, Antengene is advancing several other candidates in different stages of development, including ATG-016, ATG-527, and ATG-019, which target various oncological conditions. The company is committed to addressing unmet medical needs in Asia through its research and development efforts focused on anti-tumor and anti-cancer therapies.

TUNGEE

Series B in 2020
Guangzhou Tungee Technology Co.,Ltd., a software as a service (SaaS) company, develops intelligent sales cloud platform. It provides leads mining, business opportunity engagement, customer relationship management, and order analysis for enterprises. The company offers Tungee intelligent sales cloud platform , outbound leads, inbound leads, engage, cloud-based call center, intelligent call, and CRM products. It also offers Tungee galaxy, prophecy, and discernment solutions. Guangzhou Tungee Technology Co.,Ltd. was founded in 2016 and is based in Panyu, China.

Shukun Technology

Series B in 2020
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.

Nice Tuan

Series C in 2020
Nice Tuan is an e-commerce platform that specializes in providing daily groceries and a variety of household products. The company collaborates with local residential communities to source items from nearby warehouses and producers, ensuring a wide selection of fresh produce and essential goods for residents. By focusing on creating a convenient and efficient community e-commerce ecosystem, Nice Tuan aims to enhance the shopping experience for local consumers while supporting local suppliers.

LetsGetChecked

Series C in 2020
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Pratilipi

Series C in 2020
Pratilipi is a platform which brings readers, writers and their stories together. From the next door neighbour reading stories in the afternoon, to the funny college kid downstairs, millions of people around you are using Pratilipi to discover, express and share their stories in the language they love.

Luc Therapeutics

Series B in 2020
Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.

Yunyinggu

Series C in 2020
Yunyinggu Technology Co., Ltd. is a start-up company dedicated to developing and promoting new display technologies that can significantly improve the performance of flat panel displays. The company's proprietary solution is the world's best in achieving high PPI (pixel per inch) and can be applied to all kinds of flat panels such as LCD, LED, OLED and others. Yunyinggu Technology Co., Ltd. is based in China.

Belief Biomed

Debt Financing in 2020
Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

Shulan Health

Series C in 2020
Shulan Hospital is a hospital center that provides rehabilitation, nutrition, health examination, and remote-consultation services.

DiNovA Medtech

Series C in 2020
Weiqiang Medical Technology develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.

Abbisko Therapeutics

Series C in 2020
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Element Science

Series C in 2020
Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietary next-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The company was founded in 2011 and is headquartered in San Francisco, California.

IntoCare

Series C in 2020
IntoCare is a high-tech company focused on the development of advanced medical devices for surgical procedures. The company specializes in powered surgical staplers, offering both reusable and disposable stapler handles. IntoCare aims to enhance surgical practices by providing reliable, intelligent, and user-friendly instruments. Through its research and development efforts, the company seeks to advance the field of surgical technology and support the marketing of nonpharmaceutical interventions, ensuring that healthcare professionals have access to innovative tools that improve patient outcomes.

Kira Pharma

Series B in 2020
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Jacobio Pharmaceuticals

Series C in 2020
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.

Bouffalo Lab

Series B in 2020
Bouffalo Lab designs and develops semiconductor chips. The company offers integrated Wi-Fi chipsets for low-power and high-performance application development and other products. Its products are used in smart homes, cities, manufacturing, robots, and wearable systems, as well as communication equipment and in-vehicle intelligent systems. The company is based in Shanghai, China.

Nice Tuan

Series B in 2020
Nice Tuan is an e-commerce platform that specializes in providing daily groceries and a variety of household products. The company collaborates with local residential communities to source items from nearby warehouses and producers, ensuring a wide selection of fresh produce and essential goods for residents. By focusing on creating a convenient and efficient community e-commerce ecosystem, Nice Tuan aims to enhance the shopping experience for local consumers while supporting local suppliers.